Drug
Galcanezumab clinical trials
Also written LY2951742 and Emgality.
- studies test it
- 32
- open now
- 2
- in phase 3
- 12
- first study started
- 2011
Keep track of what changes. Save the galcanezumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
32 studies that test it; most in 2015 (7)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2012 | 1 |
| 2014 | 3 |
| 2015 | 7 |
| 2016 | 3 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 3 |
| 2020 | 6 |
| 2021 | 1 |
| 2022 | 2 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 6
- Phase 2
- 5
- Phase 3
- 12
- Phase 4
- 8
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 25 · Other 7
Eli Lilly and Company (23) · Beth Israel Deaconess Medical Center (1) · Duke University (1) · Albany Medical College (1) · University of California, San Francisco (1) · Allergan (1) · Stanford University (1) · Xuanwu Hospital, Beijing (1)
Often tested with
Tested in the same studies.
Erenumab (3) · Eptinezumab (2) · Ubrogepant (1) · Atogepant (1) · Onabotulinum toxin A (1) · Fremanezumab (1)
Studies
Open first, then newest update. How each study uses galcanezumab is read from its arms, and is right about nine times in ten.
Testing it · 32
- Comparing Migraine Preventive Therapies vs. Anti-CGRP Therapies for Tinnitus in Patients With Migraine (COMPACT-PM)Not yet recruitingPhase 4Stanford UniversityNCT07655440Written as Galcanezumab
- Investigator Initiated Trial of Galcanezumab Treatment in Alzheimer's DiseaseRecruitingEarly Phase 1Xuanwu Hospital, BeijingNCT07323927Written as Galcanezumab
- Novel Insight Into Migraine Pathophysiolgy and Galcanezumab Mechanisms of ActionCompletedPhase 4Beth Israel Deaconess Medical CenterNCT04271202Written as Emgality 120 MG in 1 ML Prefilled Syringe
- A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic MigraineActive, not recruitingPhase 3Eli Lilly and CompanyNCT04616326Written as Galcanezumab
- Anti-CGRP for Inflammation and Pain Modulation in Small Fiber Neuropathy/FibromyalgiaCompletedPhase 4Duke UniversityNCT04158752Written as Galcanezumab
- A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic MigraineActive, not recruitingPhase 3Eli Lilly and CompanyNCT03432286Written as Galcanezumab
- The Effect of Galcanezumab-gnlm on Post-Traumatic, Migrainous HeadachesCompletedPhase 4Albany Medical CollegeNCT06901518Written as Galcanezumab-Gnlm
- Galcanezumab for Vestibular MigraineCompletedPhase 2University of California, San FranciscoNCT04417361Written as Galcanezumab Prefilled Syringe
- A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic MigraineCompletedPhase 4Eli Lilly and CompanyNCT05127486Written as Galcanezumab
- Real World Effectiveness of Eptinezumab in Participants With MigraineTerminatedPhase 4H. Lundbeck A/SNCT05284019Written as Galcanezumab
- Tandem OnabotulinumtoxinA Galcanezumab Emerging Therapeutic Headache Elimination Research StudyTerminatedPhase 4Diamond Headache ClinicNCT05492695Written as Galcanezumab
- A Study of Galcanezumab (LY2951742) in Participants With Episodic MigraineCompletedPhase 3Eli Lilly and CompanyNCT03963232Written as Galcanezumab
- Evaluation of Galcanezumab in the Prevention of Chronic MigraineCompletedPhase 3Eli Lilly and CompanyNCT02614261Written as Galcanezumab
- A Study of Gastrointestinal Emptying Time in Adult Participants With Migraine Before and After Start of a mAb CGRP AntagonistCompletedPhase 4Eli Lilly and CompanyNCT04294147Written as Galcanezumab
- A Study of LY2951742 (Galcanezumab) in Participants With Cluster HeadacheCompletedPhase 3Eli Lilly and CompanyNCT02797951Written as Galcanezumab
- A Study of Galcanezumab (LY2951742) in Healthy Chinese ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT04085289Written as Galcanezumab
- A Study of LY2951742 (Galcanezumab) in Japanese Participants With Episodic MigraineCompletedPhase 2Eli Lilly and CompanyNCT02959177Written as Galcanezumab
- Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With MigraineCompletedPhase 1AllerganNCT04179474Written as Galcanezumab
- A Study of LY2951742 (Galcanezumab) in Japanese Participants With MigraineCompletedPhase 3Eli Lilly and CompanyNCT02959190Written as Galcanezumab
- A Study of Galcanezumab in Participants With Chronic Cluster HeadacheCompletedPhase 3Eli Lilly and CompanyNCT02438826Written as Galcanezumab 300 mg
Codes
What other systems call galcanezumab · ClinicalTrials.gg INT000984
- MeSH (NLM) C000628360galcanezumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 55KHL3P693GALCANEZUMABConfirmed FDA, NLM, Wikidata
- RxNorm 2058846Confirmed FDA, Wikidata
- Wikidata Q25326707galcanezumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C166816GalcanezumabOne source FDA
- DrugBank DB14042One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000628360 | galcanezumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 55KHL3P693 | GALCANEZUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2058846 | — | Confirmed FDA, Wikidata |
| Wikidata | Q25326707 | galcanezumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C166816 | Galcanezumab | One source FDA |
| DrugBank | DB14042 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.